1
Lothar Schwink, Siegfried Stengelin, Thomas Boehme, Matthias Gossel, Gerhard Hessler, Petra Stahl: Aryl-substituted heterocycles, process for their preparation and their use as medicaments. Sanofi Aventis Deutschland, Barbara E Kurys, January 15, 2008: US07319108 (77 worldwide citation)

The invention relates to substituted aryl-substituted heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof, to process for their preparation and to their use as medicaments. Compounds of the Formula I in which the radicals have the stated meaning ...


2
EGGERT Ilona, O HARE Aidan Michael, YATES Barry, JAMES Aled Meredydd, CROSS John David: DISPOSITIF DADMINISTRATION DE MÉDICAMENT ÉQUIPÉ DUN COUVERCLE, MEDICAMENT DELIVERY DEVICE WITH CAP. SANOFI AVENTIS DEUTSCHLAND, EGGERT Ilona, O HARE Aidan Michael, YATES Barry, JAMES Aled Meredydd, CROSS John David, November 29, 2012: WO/2012/160163 (75 worldwide citation)

The invention resides in a hand-held medicament delivery device which comprises a housing containing a first electrical circuit and a battery, a medicament delivery mechanism, and a protective cap releasably securable to the housing. The housing also includes a contactless switch and the cap a switc ...


3
Anuschirwan Peyman, Eugen Uhlmann: G cap-stabilized oligonucleotides. Sanofi Aventis Deutschland, June 12, 2007: US07229974 (72 worldwide citation)

Oligonucleotides of the formula 5′-(CAP)-(Oligo)-(CAP)-3′ are disclosed where (oligo) is a nucleotide sequence of from 10 to 40 nucleotides in length, and CAP is Gm, where m is an integer of from zero to ten, the two CAP's which are present in the molecule can be defined independently of each other ...


4
Lauffer Leander, Oquendo Patricia, Zettlmeissl Gerd, Seed Brian: Proteines de fusion ayant des portions dimmunoglobulines, preparation et utilisation, Fusion proteins with immunoglobulin portions, the preparation and use thereof. Behringwerke Aktiengesellschaft, The General Hospital Corporation, Immunex Corporation, Sanofi Aventis Deutschland, BERESKIN & PARR, January 27, 2009: CA2045869 (67 worldwide citation)

The invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of the constant region of immunoglobulin molecules. The functional properties of the two fusion partners are sur ...


5
Robert Frederick Veasey, Robert Perkins, David Aubrey Plumptre: Drive mechanisms suitable for use in drug delivery devices. Sanofi Aventis Deutschland, McDonnell Boehnen Hulbert & Berghoff, December 14, 2010: US07850662 (62 worldwide citation)

A drive mechanism suitable for use in drug delivery devices is disclosed. The drive mechanism may be used with injector-type drug delivery devices, such as those permitting a user to set the delivery dose. The drive mechanism may include a housing, a dose dial sleeve, and a drive sleeve. A clutch is ...


6
Marc Nazare, Volkmar Wehner, David William Will, Hans Matter: Pyrazole-derivatives as factor Xa inhibitors. Sanofi Aventis Deutschland, Ronald G Ort, Scully Scott Murphy and Presser P C, March 22, 2011: US07910606 (61 worldwide citation)

The present invention is directed to a compound of formula I, in which R0; R1; R2; R3; R4; Q; V, G and M have the meanings indicated below. The compound of formula I is a pharmacologically active compound. It exhibits a strong anti-thrombotic effect and is suitable, for example, for the therapy and ...


7
Dominique Freeman, Dirk Boecker, Don Alden, Barry Dean Briggs, Jon Hewitt Leonard, Ray Freeman, George Gogue: Tissue penetration device. Sanofi Aventis Deutschland, Paul Davis, Goodwin Procter, June 26, 2012: US08206319 (47 worldwide citation)

A moving coil tissue penetration device includes a magnetic source that produces a magnetic field in a magnetically active region. A cylindrical coil is secured to a translation substrate and disposed at least partially within the magnetically active region. A sharpened member is configured to penet ...


8
Drive mechanisms for use in drug delivery devices. Sanofi Aventis Deutschland, May 21, 2008: EP1923083-A1 (47 worldwide citation)

The present invention relates to drive mechanisms suitable for use in drug delivery devices, in particular pen-type injectors, wherein a number of pre-set doses of medicinal product can be administered. In particular, the present invention relates to such drug delivery devices where a user may activ ...


9
Schwink Lothar, Stengelin Siegfried, Boehme Thomas, Gossel Matthias, Hessler Gerhard, Stahl Petra: (De) Arylsubstituierte heterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, (En) Aryl substituted heterocycles, method for production and use thereof as medicaments. Sanofi Aventis Deutschland, August 4, 2005: WO/2005/070925 (47 worldwide citation)

(EN) The invention relates to substituted, aryl-substituted heterocycles, the physiologically-acceptable salts and physiologically-functional derivatives thereof, methods for production and use thereof as medicaments. Compounds of formula (I), where the groups have the given meanings, the N-oxides a ...


10
Antony Bigot, Siegfried Stengelin, Gerhard Jaehne, Andreas Herling, Guenter Mueller, Franz Jakob Hock, Michael R Myers: Adenosine analogues and their use as pharmaceutical agents. Sanofi Aventis Deutschland, Barbara E Kurys, September 4, 2007: US07265111 (46 worldwide citation)

The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are independently 0, 1, 2, or 3, provided that n+p is a least 1; and unsubstituted and at least monosubstituted C1-C10-alkylene-Y, C2-C10-alkylene-Y, C3- ...